| To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia (NCT06622824) | Suzhou Kintor Pharmaceutical Inc, | 2024-10-15 |
| To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males (NCT06692465) | Suzhou Kintor Pharmaceutical Inc, | 2023-04-13 |
| Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 (NCT05428449) | Suzhou Kintor Pharmaceutical Inc, | 2022-02-10 |
| To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia (NCT05218642) | Suzhou Kintor Pharmaceutical Inc, | 2022-01-31 |
| A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (NCT04984668) | Suzhou Kintor Pharmaceutical Inc, | 2021-11-02 |
| A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects (NCT05009732) | Suzhou Kintor Pharmaceutical Inc, | 2021-09-30 |
| A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients (NCT04869228) | Suzhou Kintor Pharmaceutical Inc, | 2021-08-04 |
| GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (NCT05178043) | Suzhou Kintor Pharmaceutical Inc, | 2021-08-01 |
| To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects (NCT06468579) | Suzhou Kintor Pharmaceutical Inc, | 2021-07-25 |
| Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness (NCT04870606) | Suzhou Kintor Pharmaceutical Inc, | 2021-03-05 |
| Phase II Study Evaluating the Efficacy and Safety of KX-826 (NCT05940506) | Suzhou Kintor Pharmaceutical Inc, | 2020-09-28 |
| the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending (NCT04502901) | Suzhou Kintor Pharmaceutical Inc, | 2020-01-14 |
| The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC (NCT03899467) | Suzhou Kintor Pharmaceutical Inc, | 2019-05-30 |
| Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) (NCT03893695) | Suzhou Kintor Pharmaceutical Inc, | 2019-05-25 |